The Food Edge Podcast

Somewhere in North America, a consumer is sitting in a NECTAR booth tasting her seventh coded sample of the afternoon. She scores it zero to nine for acceptability and writes one sentence about texture. What she is doing is the most serious consumer sensory work in alt-protein. What the booth does not see is whether she ever buys the product again.This episode argues that the industry has been reading the wrong half of the sensory data. The NECTAR 2025 panel shows taste parity is closing across plant-based categories. Texture parity is not. And even where texture is approaching parity, the measurement that actually predicts commercial outcome is not the blind panel score. It is the repeat-purchase rate sitting in scan panels that most brand teams do not track with the same discipline they apply to taste tests.Twelve minutes. Two reversals. One counterintuitive call on the category type investors keep mispricing. Press play.The diagnostic question from this episode:"If the only thing you could measure about your product was repeat purchase, would you still be making the same formulation decisions?"This episode continues a four-piece FoodEdge arc. Issue 20 (rent before build), Issue 21 (downstream processing moat), Issue 23 (platforms should start as ingredient companies), and now S02E06 (taste, texture, repeat purchase). Each one is about commercial discipline coming before optionality. Read the prior posts on FoodEdge before or after listening. Get full access to What We Notice at amadamek.substack.com/subscribe

In 2021, two precision fermentation companies raised on similar promises. Vivici closed a thirty-two point five million euro Series A, backed by dsm-firmenich and Fonterra. Believer Meats raised over three hundred and forty million dollars and achieved regulatory clearance in the United States. Four years later, only one of them can still point to a document that would survive an outside audit.This episode argues that the real question about the twenty twenty-six funding market is not whether investors have learned discipline. It is whether they have noticed that the filter has moved outside the room entirely. Evidence portability, not conviction, is what is getting capital deployed now. The parties that can witness a moat from the inside are the ones writing the documents that determine which Food Biotech startups raise their next round. And the sector is still pitching the wrong companies.Twelve minutes. One reversal. One counterintuitive call on the company type everyone is mispricing. Press play.The diagnostic question from this episode:”If an investor called you tomorrow, not next week, tomorrow, and asked to see one document from your company. Not a deck. Not a data room index. Not a LinkedIn post. One document, signed by somebody outside your building, that proved your moat was real. Could you produce it?”This episode closes a three-piece arc with Issue 20 (rent before build) and Issue 21 (the downstream processing moat). Read both on FoodEdge before or after listening. Get full access to What We Notice at amadamek.substack.com/subscribe

The ultra-processed foods debate is no longer only a nutrition argument. It is infrastructure. WHO formally initiated guideline work on UPF consumption in 2025. FDA and USDA launched a joint process to build a uniform federal definition. The moment institutions create language, markets start using it as a shortcut. And shortcuts reprice categories before science fully settles them.This episode breaks down what that sequencing means for founders and investors. I am not arguing that every processed product is harmful, or that FoodTech is about to collapse under a wave of public health sentiment. I am arguing something more specific: in the next capital cycle, ultra-processed risk will become a standard screen in FoodTech diligence, alongside regulatory, margin, and formulation risk. The founders and investors who understand that now will be positioned differently from those who discover it when the term sheet changes.Thanks for reading Food Edge! This post is public so feel free to share it.We examine the evidence without pretending it is cleaner than it is. The 2024 BMJ umbrella review across forty-five meta-analyses. The 2025 Nature Medicine randomised crossover trial that matched both diets on nutritional guidelines and still found a processing signal. What the data actually proves, what it does not prove, and why the burden of explanation has shifted from regulators to founders.From there, I introduce a three-bucket framework: processing-defensible, processing-tolerable, and processing-fragile. The third bucket gets hit first. The uncomfortable part is that a significant share of the market currently believes it sits in bucket one.The broader message is structural. A 2026 Deloitte survey found that sixty-eight percent of Americans viewed ultra-processed foods as worse for health, whilst sixty-nine percent could not explain what ultra-processed foods actually are. High suspicion, low understanding, fast judgment. That is not a communications problem. That is a valuation problem in slow motion.If you are four to twelve weeks from investor conversations, this episode is a stress test of your processing narrative. Can you explain in one sentence why your product is made the way it is? If definitions tighten, does your story get stronger or weaker? And which processing steps are genuinely necessary, versus inherited from a decade of convenience logic nobody ever questioned?What looks like nutrition debate today becomes valuation logic tomorrow.Listen to the episode. And audit your processing architecture before investors do.- Adam Get full access to What We Notice at amadamek.substack.com/subscribe

Japan’s recent FoodTech upgrade is not a public relations moment. It is a structural signal. By naming FoodTech a national strategic sector alongside artificial intelligence and semiconductors, Japan has flipped the order of innovation: policy first, infrastructure second, evidence third, narrative last.This episode breaks down what that sequencing means for founders and investors. We analyse Japan not as a hype cycle, but as an evidence engine, from cellular agriculture infrastructure to population-scale microbiome datasets. The key insight is simple: when governments fund infrastructure that generates longitudinal data, founders inherit credibility before they even pitch.We then examine the genome-edited high GABA tomato as a case study in the Narrative-Evidence Gap. Mechanism and regulatory clearance were not enough. Trust-layer evidence lagged. Distribution hesitated. The lesson is clear: regulatory approval does not automatically convert into consumer legitimacy.From there, we build an evidence credibility ladder using recent FoodBioTech moves. Regulatory status as a distribution ticket. Steel and concrete as proof of scalability. Infrastructure monetisation as strategic defensibility. Supply-chain piggybacking as accelerated validation. The common thread is that serious players are presenting regulators, factories, tools, and data assets as proof, not adjectives.The broader message is structural. In two thousand twenty six, geography determines where lab data, plant economics, regulatory dossiers, and trust signals can actually be built. Fundraising narratives that ignore this layer risk becoming innovation theatre at the national scale.If you are raising capital within the next twelve to eighteen months, this episode is a stress test of your geography story. Can your chosen country generate decision-grade evidence fast enough to support your claims, or are you relying on slides and assumptions?I recommend following Jasper Sturtewagen, whose writing dissects European innovation, policy architecture, and capital allocation with unusual clarity and structural depth.You can subscribe to his Substack here:Listen to the episode. And audit your geography before investors do.- Adam Get full access to What We Notice at amadamek.substack.com/subscribe

Food as Medicine 3.0 marks a structural shift, not a trend. Appetite-suppressing GLP-1 drugs, AI-driven multi-omics, and tightening regulation are forcing food to behave less like lifestyle branding and more like pharmaceutical infrastructure. This episode breaks down how drug-led appetite control is already reshaping food demand, shrinking calorie intake, and pushing brands toward nutrient density, digestive tolerance, and dosing-aware design rather than volume and indulgence.We explore how food is moving from macronutrients to molecules, targeting inflammation, metabolic markers, microbiome modulation, and aging pathways with measurable outcomes. What once lived in academic journals is now entering commercial pipelines, backed by biomarker data, clinical-style validation, and regulatory dossiers. The real bottleneck is no longer technology, but alignment between evidence, claims, and governance across regions.The episode also maps the regulatory divergence shaping winners and losers. The EU advances through evidence-led claims and public-private partnerships, the US navigates gray zones under FDA oversight and payer pressure, and Asia experiments with rapid pilots and digital health integration. On the investment side, capital is concentrating around platforms that prove impact, integrate diagnostics, and speak the language of regulators and insurers, not just consumers. The core message is simple: food that cannot demonstrate measurable therapeutic value will struggle to survive in a drug-shaped nutrition economy.I recommend following Valentina Chiran-Buda, whose work treats quality, food safety, sustainability, and health as one coherent system rather than disconnected disciplines.You can subscribe to her Substack here: where she publishes her notes on how science, regulation, culture, and trust intersect in real-world food systems.Listen to the podcast episode! And enjoy. - Adam Get full access to What We Notice at amadamek.substack.com/subscribe

Every year, investors tell me they wish they had found certain companies earlier. Not the obvious ones everyone chased. The quiet ones that compounded.The difference between early identification and late discovery is not better prediction about technology breakthroughs. It is not insider access to deal flow. It is knowing which questions to ask and understanding what the answers actually reveal.After years evaluating FoodBioTech companies, the pattern is consistent. Winners share structural characteristics that are visible early if you look in the right places. Regulatory pathway portfolios, not single filings. Cost physics that respond to scale, not structural constraints that volume cannot touch. Signed commercial commitments, not “strong interest from major CPGs.”Most evaluation focuses on the story. The pitch. The vision. But stories are easy to craft. Structure is hard to fake. These twelve questions, organised across Regulatory Readiness, Manufacturing Reality, Commercial Foundation, and Capital Resilience, surface the structure underneath the story.In 2026, the funding environment is selective. Capital is concentrating on companies that deserve it. The investors who can identify structural winners systematically will build portfolios that outperform. The founders who understand what sophisticated investors actually assess will position themselves to attract that capital.The winners are not the companies with the best stories. They are the companies with the best structures underneath the stories. These twelve questions help you find them.Listen to the podcast episode! And enjoy. - AdamP.S. read more: Get full access to What We Notice at amadamek.substack.com/subscribe

GLP-1 isn’t a wellness trend. It’s a demand shock disguised as a prescription.Most food companies are treating semaglutide like a reformulation brief, smaller portions, more protein, lighter claims. That’s the comfortable response. It’s also the wrong level of thinking.Because GLP-1 doesn’t just reduce appetite. It changes the state in which people make food decisions. Less urgency. Less impulse. Less “I’ll just have something.” More moments where the consumer looks at food and feels... nothing.That creates a new competitor most brands aren’t built to fight: “not bothered”.If you’ve built growth on frequency, snacking occasions, and frictionless temptation, GLP-1 is not a headwind. It’s a redesign of the game. It shifts indulgence from intensity to permission, it changes what feels worth eating, and it forces innovation to compete on trust, precision, and fit with a quieter physiology.This episode connects the dots most people ignore: GLP-1 as a cultural rewrite of eating, not just a change in the basket. And why the next decade of food innovation will be won by the products people still choose when wanting becomes optional.GLP-1 didn’t kill indulgence, it killed autopilot, and food innovation now has to earn every bite.Listen to the podcast episode! And enjoy. - AdamP.S. read more: Get full access to What We Notice at amadamek.substack.com/subscribe

Something profound happened in Singapore’s biotech district last month that will fundamentally reshape how every food biotechnology company approaches their geographic strategy. While European founders wait 18-36 months for EFSA Novel Food approvals that may never arrive, a precision fermentation startup received Singapore regulatory authorisation in 240 days and immediately began scaling production. This wasn’t an outlier. This is the new normal in Asia, where China now captures over 75% of all Asia-Pacific biotech investments and high-value licensing deals exceeding $50 million have surged sixfold since 2020.The stark divergence is accelerating. Recent years have witnessed a major shift in funding, talent placement, and commercialisation speed, with Singapore emerging as a model of regulatory efficiency whilst Europe remains mired in lengthy approval timelines, fragmented markets, and a culture that prizes research over rapid application despite its world-class science base.So here we are, watching Europe invent tomorrow whilst Asia commercialises it todayTo appreciate why this development matters, we must first understand what makes Asia’s coordinated strategy fundamentally different from Europe’s fragmented approach. This isn’t about superior science - Europe’s research base remains world-class. This is about institutional commitment to translating research into commercial outcomes rather than treating innovation as academic exercise requiring bureaucratic containment.The numbers tell the story: China’s biotech venture capital dominance didn’t happen by accident. It resulted from deliberate policy decisions to prioritize commercialization speed, streamline regulatory frameworks, and deploy billions in coordinated government support. Meanwhile, Europe’s EFSA processes consume 18-36 months per approval whilst Asian regulators complete assessments in 4-8 months.What does Asia’s biotech infrastructure deliver?This is no ordinary competitive advantage. Asia’s model represents a fundamental shift in how governments approach food innovation, designed to attract exactly the capital-intensive biotechnology that Europe systematically repels. The specifications reveal institutional commitment:* 9-12 months regulatory approvals in Singapore versus 18-36 month EFSA bottlenecks, enabling 3-4x faster commercialisation* 75% of Asia-Pacific VC flowing to China, creating concentrated capital deployment that European fragmentation cannot match* 6x increase in deals exceeding $50 million since 2020, demonstrating investor confidence in Asian commercialization pathways* S$28 billion Singapore RIE 2025 plan providing coordinated support across research, manufacturing, and scale-up* Tech.Pass visa programs recruiting global talent with 4-6 week processing versus Europe’s byzantine immigration systems* South Korea’s $1.6 billion KDDF committed to over 1,200 biotech projects with streamlined approval processes* Japan’s $366 million Bioventure Support Program deploying capital to nurture startups through commercialization* India’s BIRAC grants fueling innovation through steady funding streams and low-interest loans* Proactive IP protection frameworks in Singapore attracting multinationals seeking stable jurisdictions for billion-dollar investmentsThis represents more than operational efficiency. It demonstrates the economic viability of infrastructure that captures the $7.5 trillion food biotech opportunity whilst Europe processes documentation.Why this matters nowAsia’s coordinated biotech strategy signals something far larger than approval timelines or funding amounts. Three developments make this a watershed moment for food biotechnology geography:1. Capital follows certainty, and Asia engineered regulatory certainty as competitive weapon.China’s 75% capture of Asia-Pacific biotech VC didn’t result from superior science - it resulted from regulatory frameworks that enable investors to underwrite commercialisation timelines with confidence. The venture math is brutal: identical technology, identical team, but Singapore location enables exit modeling within 36-48 months whilst European location makes exit timeline unknowable due to EFSA uncertainty. High-value deals surging sixfold in China since 2020 whilst European food biotech struggles to close Series B rounds documents the capital reallocation in progress.2. The talent exodus compounds Europe’s disadvantage.Europe trains world-class scientists through excellent university programs, then systematically repels them through regulatory dysfunction preventing commercial translation. Singapore’s Tech.Pass visa enables PhD-level talent to relocate within 4-6 weeks whilst Europe’s immigration systems treat globally-mobile innovation talent as administrative burdens. The brain drain creates compounding disadvantage - Europe funds the research, Asia captures the commercialization and the scientists who enable it.3. Manufacturing capacity follows regulatory certainty.Precision fermentation requires $127-153 million facility investments with 18-month construction timelines. No rational CFO commits that capital to jurisdictions where regulatory approval remains uncertain 36 months post-submission. China’s precision fermentation capacity expanding at 40% annually whilst European capacity stagnates documents the infrastructure investment following Asia’s regulatory certainty. Perfect Day’s $144 million lawsuit against Italian manufacturing partner Olon demonstrates exactly why European co-manufacturing strategies fail when regulatory timelines destroy partnership economics.What every #biotech founder should do nowIf you are building precision fermentation, cellular agriculture, or novel ingredients in Europe, here is your geographic arbitrage playbook:Calculate your burn rate under Singapore versus EFSA timelines immediately.Run financial projections assuming 9 months Singapore approval versus 24-month EFSA limbo. At €300,000 monthly burn, EFSA’s regulatory timeline consumes €7.2 million whilst Singapore consumes €1.2 million - a €6 million capital efficiency advantage before selling a single kilogram. European regulatory timelines force founders to raise additional €8-15 million bridge rounds purely to survive EFSA processing, creating massive dilution that destroys founder economics even if approval eventually succeeds.Map your total addressable market assuming Asia-first strategy.Singapore approval doesn’t just unlock Asian markets - it provides regulatory precedent accelerating approvals in pragmatic jurisdictions including Canada, UAE, and select US states. Asian markets represent 60% of global food biotechnology demand. The geographic arbitrage isn’t just regulatory - Asian manufacturing capacity costs 30-40% less than European equivalents due to energy pricing, labor costs, and integrated supply chains. Combined advantages approach 50-60% total cost structure improvement.Contact Singapore Economic Development Board this week.The EDB maintains dedicated biotech support teams specifically designed to accelerate company relocation and scaling. They provide facility incentives, regulatory pathway guidance, and partnership infrastructure that European jurisdictions simply don’t offer. The window for geographic arbitrage remains open but closing rapidly as first movers capture regulatory precedents, partnership relationships, and talent pools creating compounding advantages.A four-week competitive repositioning sprintWeek 1* Audit current regulatory strategy against Asia-Europe divergence. Calculate exact costs of EFSA timeline versus Singapore alternative including burn rate, bridge funding dilution, and opportunity cost of delayed market entry. Model total addressable market under Asia-first versus Europe-first strategies.* Interview 12 food biotech founders who navigated both European and Asian regulatory pathways. Pattern recognition from peer conversations reveals strategic insights desk research misses.Week 2* Engage Singapore EDB to understand… Get full access to What We Notice at amadamek.substack.com/subscribe

Something profound happened on the streets of Zurich this week that will fundamentally reshape how every food delivery company approaches their business model. While the headlines focus on the novelty of robot dogs carrying takeout orders, the real story lies in the economic transformation these machines represent and what their deployment signals about the future of last-mile logistics.Just Eat Takeaway, the Dutch delivery giant with €2 billion in annual revenue, has launched Europe's first commercial pilot of autonomous ground robots in partnership with Swiss robotics company RIVR. These are not prototype demonstrations or controlled laboratory tests. These are real customers ordering real food through the Just Eat app and receiving their meals via autonomous robots navigating actual urban environments.So here we are, talking to machines about lunchTo appreciate why this development matters, we must first understand what makes these robots fundamentally different from previous autonomous delivery attempts. RIVR's machines represent a hybrid approach that combines wheels for efficient street travel with articulated legs capable of climbing stairs and navigating curbs. The deployment begins immediately, with expansion to additional European cities planned for the end of 2025 and potential applications in retail and convenience stores already confirmed.What does RIVR's robot deliver?This is no ordinary delivery drone. RIVR's autonomous ground robot represents a fundamental shift in last-mile economics, designed to operate profitably in Europe's most expensive labour market. The specifications reveal serious commercial intent:* Hybrid locomotion system combining wheels for 15 km/h street speed with articulated legs for climbing stairs and kerbs* 40-litre cargo capacity with internal walls preventing spillage during transport* 30-kilometre operational range per battery charge, enabling multiple delivery cycles daily* All-weather operation certified for rain, snow, high heat, and wind conditions* Live monitoring infrastructure with human operators overseeing multiple robots from centralised control centres* QR code customer unlock system with secure cargo compartment locking mechanisms* €0.40 per kilometre operating cost compared to $1.60 per delivery for human drivers* 18-month payback period making capital expenditure decisions commercially viable today* Regulatory approval from Swiss authorities with specific operational parameters for European urban environmentsThis represents more than operational efficiency. It demonstrates the economic viability of infrastructure that reduces delivery costs by 96 percent whilst maintaining service quality standards.Why this matters nowJust Eat Takeaway's Zurich deployment signals something far larger than cost savings. Three developments make this a watershed moment for food delivery business models:1. Autonomous delivery has moved from prototype to commercial deployment.Until recently, robot delivery existed primarily in controlled environments or university campuses. Now Europe's largest food delivery platform is processing real customer orders through autonomous systems in live urban conditions. The technology has crossed the threshold from experimental to operationally viable.2. The Swiss validation solves the European scalability question.Switzerland represents the ultimate stress test for autonomous delivery economics. High labour costs, strict regulations, and challenging weather conditions create the most demanding operational environment in Europe. Success in Switzerland proves viability across all major European markets, eliminating the primary uncertainty about continental expansion.3. The infrastructure enables entirely new business models.When delivery costs drop from $1.60 to $0.06 per transaction, every assumption about optimal kitchen locations, order minimums, delivery radii, and customer segmentation becomes obsolete. Companies that redesign their operational models around near-zero delivery costs will gain permanent competitive advantages over those optimising for human driver economics.What every #foodtech founder should do nowIf you are building food delivery, dark kitchens, or on-demand services, here is your strategic playbook:Model your unit economics at 96 percent lower delivery costs.Run financial projections assuming delivery expenses drop from current levels to essentially the cost of electricity plus remote monitoring. What markets become profitable? What order sizes become viable? What customer segments can you serve?Redesign your fulfillment geography.Current kitchen locations optimise for balancing rent costs against delivery efficiency under human driver economics. Autonomous delivery enables smaller, more distributed preparation facilities that prioritise customer proximity over centralised scale. Map where your micro-fulfillment centres should be located when delivery costs approach zero.Prepare for the regulatory framework expansion.Swiss approval processes often template EU-wide regulations. Study Zurich's specific operational conditions - 15 km/h speed limits, pedestrian yielding requirements, monitoring infrastructure mandates—and align your autonomous delivery specifications with these precedents to accelerate approval in other markets.A two-week competitive positioning sprintWeek 1* Analyse your current delivery cost structure and identify which expenses disappear with autonomous systems. Map your existing kitchen locations against optimal placement assuming 96 percent delivery cost reduction. Calculate how order minimums, delivery fees, and service radii change when delivery approaches zero cost.* Interview 15 customers about their willingness to receive autonomous deliveries and preferences for interaction with robotic systems. Test messaging around delivery time windows, unlock procedures, and service reliability expectations.Week 2* Prototype three operational models: current human delivery optimisation, hybrid human-robot deployment, and fully autonomous delivery scaling. Model customer acquisition costs, lifetime value calculations, and competitive positioning under each scenario.* Contact autonomous delivery technology providers to understand deployment timelines, operational requirements, and partnership structures. Evaluate whether your business model benefits from early integration or whether following proven deployment models provides better risk management.* Develop contingency plans for competitive responses when autonomous delivery becomes standard in your market. Identify which operational advantages you can maintain and which require fundamental business model changes.Industry implications and what to watch* If RIVR's Zurich deployment demonstrates sustained profitability, expect rapid expansion announcements from Just Eat Takeaway across major European cities by Q4 2025, followed by competitive responses from Deliveroo, Uber Eats, and regional platforms.* Watch for regulatory harmonisation across EU markets as Swiss operational frameworks become templates for continental deployment standards. Companies developing autonomous delivery capabilities should align technical specifications with Zurich precedents.* Monitor shifts in dark kitchen and micro-fulfillment strategies as delivery economics change. When delivery costs drop 96 percent, the optimal balance between facility locations, inventory distribution, and customer proximity changes dramatically.* Manufacturers and technology providers should prepare for massive scaling requirements. RIVR expects customers to demand tens of thousands of robots within four years, creating network effects that favour early adopters and make market entry increasingly difficult for followers.SummaryThe robots delivering meals through Zurich represent more than operational improvements -they prove the commercial viability of infrastructure that makes 96 percent delivery cost reductions achievable today. Just Eat Takeaway's partnership with RIVR eliminates t… Get full access to What We Notice at amadamek.substack.com/subscribe

Danone has launched Oikos Fusion, a cultured dairy drink developed specifically for people taking GLP-1 weight-loss medications. Initially, this carefully formulated beverage will be available exclusively in the United States, beginning in Walmart stores this August, with a broader distribution scheduled for Target, Kroger and Wakefern in October. As of now, there is no indication of any launch in Europe, leaving a sizeable opportunity open to innovators across the Atlantic.What does Oikos Fusion deliver?This is no ordinary drink. Oikos Fusion is a 7-ounce (roughly 200 ml) nutrient-dense beverage designed to meet the nutritional challenges faced by GLP-1 consumers. It contains:* 23 g of complete protein, enriched with a patented blend of whey, leucine and vitamin D* 5 g of prebiotic fibre to support digestive health* Vitamins B3, B12 and A, with vitamin D also contributing to bone and immune support* 0 g of added sugar, no artificial sweeteners, no synthetic colours or dyes* Lactose-free format and just 130 kcal per bottle* Available in three flavours: strawberry, mixed berry, and vanilla* Priced at approximately USD 2.12 per bottle in Walmart storesThis formulation reflects more than a functional drink. It distils scientific insight and consumer behaviour into a compact, satisfying format that meets emerging needs.Why this matters nowDanone’s move with Oikos Fusion signals something much larger than a new SKU. Three key reasons make this launch a watershed moment:1. GLP-1 users have officially become a shelf segment.Until recently, GLP-1 consumers were mentioned only in investor decks and trend reports. Now they have a product made expressly for them, in a familiar format, sitting on mainstream shelves.2. The formula aligns with cutting-edge nutritional guidance.Medical and nutritional experts emphasise that people using GLP-1 medications risk losing muscle mass - reportedly up to 20 % of their weight loss can be muscle rather than fat. The scientific consensus is clear: protein, leucine and vitamin D help preserve lean mass, and prebiotic fibre aids digestive comfort during appetite suppression. Oikos Fusion brings all these together with precision.3. Retailers are set to follow suit fast.Labels like “GLP-1 friendly” are not regulated, but you can expect them to appear soon on shelves and in online filters. With Conagra and Nestlé already testing formats geared for GLP-1 users, this trend is becoming mainstream.What every #foodtech founder should do nowIf you’re innovating in nutrition or functional food, here’s your playbook:* Segment deeply, not broadly.GLP-1 users are not homogenous. Some prioritise muscle retention, others need gut comfort, while others seek satiety with limited portions. Design with specific user “jobs-to-be-done” in mind.* Adapt to changing shopping baskets.GLP-1 households generally spend less and prefer small-format options. A drink under three pounds? That’s smart placement.* Keep claims compliant and consistent.Avoid medical language on the pack. Use structure-function statements like “supports muscle health” or “high-protein.” If you reference GLP-1, do it via your digital channels or disclaimers.A two-week innovation sprintWeek 1* Conduct 15 interviews with current GLP-1 users, stratified by presence or absence of side-effects.* Draft behaviour maps: what they crave at 11 am, what they struggle to digest, what tastes they prefer when appetite is low.Week 2* Prototype three micro-batches:* Whey-based protein with leucine,* Plant-based blend with added leucine,* Two portion sizes - around 100 kcal and closer to 150 kcal.* Pitch to a regional retail buyer as a “GLP-1 essentials starter set”. Highlight protein grams clearly, and include a QR code linking to a nutrition hub for GLP-1 users.* On-pack messaging: stick to nutrition details - calories, protein, fibre, sugar. Reserve GLP-1 explanation for your website or insert.Industry implications and what to watch* If Oikos Fusion gains traction at Walmart, expect fast follower activity across categories - dairy, RTDs, bars, savoury snacks.* Watch media narratives around GLP-1 affordability and appetite patterns. Trends in news coverage influence category formation.* Manufacturers: be prepared to white-label or co-develop smaller format high-protein, gut-friendly products for this emerging micro-market.SummaryDanone’s Oikos Fusion is more than a dairy drink - it’s a de facto category birth. Fewer than 10 % of Americans use GLP-1, but they are early adopters and highly motivated shoppers. If you’re building a product in foodtech, this is a demand signal: a lean, protein-focused, gut-friendly, GLP-1-equipped format needs to be on your roadmap yesterday. The only question is whether you’ll act first—or catch up later.Sources* “Danone targets consumers taking weight loss drugs with new drink” – https://www.reuters.com/business/healthcare-pharmaceuticals/danone-targets-consumers-taking-weight-loss-drugs-with-new-drink-2025-08-11* “Danone launches Oikos yogurt drink aimed at GLP-1 users” – https://www.fooddive.com/news/danone-launches-oikos-yogurt-drink-aimed-at-glp-1-users/756216/* “Oikos Fusion launch: exclusive interview with Rafael Acevedo” – https://www.foodbev.com/news/oikos-fusion-launch-exclusive-interview-with-rafael-acevedo-president-of-yogurt-at-danone/* “Danone Launches Oikos Fusion, a Yogurt-Based Drink for GLP-1 Users and Weight Loss Consumers” – https://www.preparedfoods.com/articles/130791-danone-launches-oikos-fusion-a-yogurt-based-drink-for-glp-1-users-and-weight-loss-consumers* “Danone launches innovation for weight-loss medication users” – https://www.retaildetail.eu/news/food/danone-launches-innovation-for-weight-loss-medication-users/ Get full access to What We Notice at amadamek.substack.com/subscribe